Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

Since the days of Dr. Alzheimer himself, there has been a dream that severe senility might have an explanation — and a cure. The search for both has never been more urgent. By Robert Kolker For his ...

Whether you use AI all the time or are a newcomer, the tech is changing so rapidly that it can be hard to keep up. Here are some of the key words that have been popping up in the news — and are likely ...

In the high-tech, high-competition AI field, we are seeing new versions of models rolled out by the frontier companies (OpenAI, Google and Anthropic) every month and a half. I included a Release ...

Terry Taylor is worth about $2 billion, and you have almost surely never heard of him. Based in Florida, he doesn’t put his name on the car dealerships that he buys up, and he reportedly attends ...

Top executives at three of the nation’s leading AI labs are calling for a slowdown in the development of advanced artificial intelligence. The comments are a rare display of consensus among competing ...

Anthropic and OpenAI researchers raised fresh concerns about recursive self-improvement, the process by which AI helps improve the development of models. Both OpenAI and Anthropic have in recent ...

In case you've faced some hurdles solving the clue, Easy to understand, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, and test ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.